Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
SEC Accession No. 0001193125-26-239481
Filing Date
2026-05-26
Accepted
2026-05-26 16:38:11
Documents
2

Document Format Files

Seq Description Document Type Size
1 DEFA14A d124531ddefa14a.htm DEFA14A 19850
2 GRAPHIC g124531g35h76.jpg GRAPHIC 17902
  Complete submission text file 0001193125-26-239481.txt   45670
Mailing Address 4930 DIRECTORS PLACE, SUITE 500 SAN DIEGO CA 92121
Business Address 4930 DIRECTORS PLACE, SUITE 500 SAN DIEGO CA 92121 (858) 500-8800
Kura Oncology, Inc. (Filer) CIK: 0001422143 (see all company filings)

EIN.: 611547851 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEFA14A | Act: 34 | File No.: 001-37620 | Film No.: 261020541
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)